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Abstract 
Purpose: We assessed feasibility and safety of extracorporeal carbon dioxide removal  (ECCO2R) to facilitate ultra-pro-
tective ventilation (VT 4 mL/kg and PPLAT ≤ 25 cmH2O) in patients with moderate acute respiratory distress syndrome 
(ARDS).
Methods: Prospective multicenter international phase 2 study. Primary endpoint was the proportion of patients 
achieving ultra-protective ventilation with  PaCO2 not increasing more than 20% from baseline, and arterial pH > 7.30. 
Severe adverse events (SAE) and  ECCO2R-related adverse events  (ECCO2R-AE) were reported to an independent data 
and safety monitoring board. We used lower  CO2 extraction and higher  CO2 extraction devices (membrane lung 
cross-sectional area 0.59 vs. 1.30 m2; flow 300–500 mL/min vs. 800–1000 mL/min, respectively).
Results: Ninety-five patients were enrolled. The proportion of patients who achieved ultra-protective settings by 8 h 
and 24 h was 78% (74 out of 95 patients; 95% confidence interval 68–89%) and 82% (78 out of 95 patients; 95% con-
fidence interval 76–88%), respectively.  ECCO2R was maintained for 5 [3–8] days. Six SAEs were reported; two of them 
were attributed to  ECCO2R (brain hemorrhage and pneumothorax).  ECCO2R-AEs were reported in 39% of the patients. 
A total of 69 patients (73%) were alive at day 28. Fifty-nine patients (62%) were alive at hospital discharge.
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Introduction
Mechanical ventilation may cause a form of injury (venti-
lator-induced lung injury, VILI) that is clinically indistin-
guishable from the acute respiratory distress syndrome 
(ARDS) [1, 2]. The ARDSNet investigators demonstrated 
that limiting tidal volume (VT) to 6  mL/kg of predicted 
body weight (PBW) and end-inspiratory plateau pressure 
(PPLAT) to ≤ 30 cmH2O improves survival [3], but in some 
patients these settings may not be fully protective [4, 5]. 
Reduction of VT to 3–4  mL/kg and PPLAT ≤ 25  cmH2O 
has been proposed to further minimize the risk of VILI 
[6], but this entails a significant risk of severe respiratory 
acidosis [7].
Extracorporeal carbon dioxide removal  (ECCO2R) can 
minimize this acidosis by clearing carbon dioxide  (CO2). 
In this way, less  CO2 has to be eliminated from the lungs 
enabling strategies that are more lung protective than the 
ARDSNet strategy. Such strategies might improve out-
comes by (a) using VT as low as 3–4 mL/kg and further 
decreasing PPLAT below 30  cmH2O (often termed ultra-
protective strategy [6, 8–11], (b) decreasing respiratory 
rates [12], and/or (c) minimizing driving pressures [13] or 
mechanical power [14].
Several  ECCO2R devices have recently been made 
available utilizing blood flow rates ranging from about 
450 mL/min to 1000 mL/min, but there is a lack of data 
demonstrating how effective these devices would be in 
eliminating  CO2 and hence supporting any of these lung 
protective strategies [15]. We therefore performed a mul-
ticenter, international study in patients with moderate 
ARDS to determine the feasibility and safety of  ECCO2R 
to inform the design of a future randomized clinical trial. 
The primary endpoint was the number of patients who 
successfully achieved a VT of 4 mL/kg PBW with  PaCO2 
not increasing more than 20% from baseline with a value 
of arterial pH > 7.30. Secondary endpoints included (a) 
assessment of physiological variables during ultra-pro-
tective strategy and (b) frequency of adverse events.
Methods
The study was approved by institutional review boards at 
each of the 23 study sites. Informed consent was obtained 
from patients or legally authorized surrogates. Patients 
with moderate ARDS  (PaO2/FiO2 100–200 mmHg, with 
PEEP ≥ 5  cmH2O) [16], > 18  years old, and expected to 
receive invasive mechanical ventilation for > 24  h were 
included. Exclusion criteria were decompensated heart 
insufficiency or acute coronary syndrome; severe chronic 
obstructive pulmonary disease; major respiratory aci-
dosis with  PaCO2 > 60 mmHg; acute brain injury; severe 
liver insufficiency (Child–Pugh scores > 7) or fulminant 
hepatic failure; heparin-induced thrombocytopenia; 
contraindication for systemic anticoagulation; plate-
let < 50  G/L; patient moribund, decision to limit thera-
peutic interventions; catheter access to femoral vein or 
jugular vein impossible; pneumothorax; refused consent; 
inclusion in other trials (ClinicalTrials.Gov Identifier 
NCT02282657). Study protocol is available online.
We used the Hemolung Respiratory Assist System 
(ALung Technologies, Pittsburgh, USA), the iLA activve 
(Novalung, Heilbronn, Germany) and the  Cardiohelp® 
HLS 5.0 (Getinge Cardiopulmonary Care, Rastatt, Ger-
many) devices. The first device employs a membrane lung 
with a cross-sectional area of 0.59  m2 and is run at an 
extracorporeal blood flow between 300 and 500 mL/min 
(lower extraction). The other two devices employ mem-
brane lungs of 1.30 m2 and blood flows to 800–1000 mL/
min1 (higher extraction). Each center was assigned one 
device for the purposes of the trial on the basis of that 
center’s previous experience with the specific devices.
After enrollment, sedation and neuromuscular block-
ade were administered for a minimum of 24  h. VT was 
set at 6  mL/kg PBW and positive end-expiratory pres-
sure (PEEP) was adjusted to obtain a PPLAT between 28 
and 30  cmH2O [17]. Percutaneous vascular access was 
provided using a double lumen catheter inserted in the 
internal jugular vein or in the femoral vein. Sweep gas 
flow was set to zero (baseline). Continuous infusion of 
Conclusions: Use of  ECCO2R to facilitate ultra-protective ventilation was feasible. A randomized clinical trial is 
required to assess the overall benefits and harms.
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Take‑home message 
Use of  ECCO2R to facilitate ultra-protective ventilation is feasible. A 
randomized clinical trial is required to assess the overall benefit and 
harm
1 Blood flow with the iLA activve (Novalung) and  Cardiohelp® HLS 5.0 
(Getinge) can range between 0.5 and 4.5  L/min, but was limited by study 
protocol to 800–1000 mL/min.
unfractionated heparin was used to maintain values of 
activated partial thromboplastin time (aPTT) in the 
range 35–80 s.2
VT was reduced to 4 mL/kg PBW in three steps (from 
6.0 to 5.0, from 5.0 to 4.5, and from 4.5 to 4 mL/kg PBW). 
At each step, PEEP was titrated to a target PPLAT of 
23–25 cmH2O [6, 8–11]. Sweep gas and blood flow were 
set to maintain a partial pressure of arterial  CO2  (PaCO2) 
between 80% and 120% of the baseline value. If  PaCO2 
exceeded 75 mmHg and/or pH was < 7.30 despite optimal 
 ECCO2R settings and a respiratory rate of 35  breaths/
min, VT was increased to the last previously tolerated 
value.
ECCO2R and ultra-protective ventilation were contin-
ued, and data collected (baseline, 8  h, and 24  h). After 
completing the study protocol, the attending physician 
determined the ventilatory strategy and use of  ECCO2R, 
and  ECCO2R settings as well as physiological variables 
were recorded until  ECCO2R discontinuation. Patients 
were monitored for adverse events until hospital dis-
charge or day 28 after enrollment, whichever came first.
The primary outcome was the number of patients who 
successfully achieved a VT of 4 mL/kg PBW with  PaCO2 
not increasing more than 20% from baseline with a value 
of arterial pH > 7.30.3 Duration of  ECCO2R was recorded.
Secondary endpoints included (a) assessment of physi-
ological variables and  ECCO2R settings and (b) frequency 
of adverse events.
Severe adverse events (SAE) in the trial were defined as 
(1) any fatal or immediately life-threatening event, per-
manently disabling, severely incapacitating, or requir-
ing prolonged hospitalization, or any event jeopardizing 
the patient and requiring medical or surgical interven-
tion and that the attending physician perceived might be 
directly related to  ECCO2R; (2) any clinically important 
untoward medical occurrence that was different from 
what is expected in the clinical course of ARDS. Inves-
tigators reported severe adverse events to the clinical 
coordinator. An independent data and safety monitor-
ing board (DSMB) received a detailed written report and 
evaluated whether the SAE was attributable to  ECCO2R. 
SAE were considered to be study-related if the event fol-
lowed a reasonable sequence from a study procedure and 
could readily have been produced by the study proce-
dure. SAE were not study related if they were thought to 
be primarily related to the underlying disease or to ARDS 
and its sequelae.
Other adverse events not fulfilling the above defini-
tion were recorded as  ECCO2R-related adverse events 
 (ECCO2R-AE) and classified as previously described 
[6, 8–11] as mechanical or clinical. Definitions of 
 ECCO2R-AE are provided in the online supplement.
Length of invasive mechanical ventilation, survival 
at day 28, and survival at hospital discharge were also 
recorded.
Power and data analysis
On the basis of previous data [6, 8–11] we predicted that 
(a)  PaCO2 with 6 mL/kg would be 40–60 mmHg; (b) the 
reduction of VT to 4  mmHg would increase  PaCO2 to 
65–85 mmHg. To demonstrate the ability of  ECCO2R to 
re-establish  PaCO2 values close to the ones observed with 
a VT of 6 mL/kg (± 20%) we estimated that a sample size 
of 90 patients would detect a proportion of patients who 
successfully achieved this condition with a two-sided 95% 
confidence interval of 70–90% when incidence is 80% and 
54–75% when incidence is 65%. In both estimates, the 
width of confidence interval is 0.211. For calculation of 
two-sided confidence intervals for the single proportion, 
we used the Clopper–Pearson method. To take into con-
sideration a possible 3% of dropout due to  ECCO2R mal-
function the sample size was increased to 100 patients.
To ensure quality control, (a) data were collected and 
checked for consistency before the analysis was final-
ized; (b) queries to confirm or correct outlier values were 
directly sent to local investigators; (c) analyses were per-
formed by a researcher (TP) who did not participate in 
data collection and was not a member of the study steer-
ing committee.
Continuous variables are reported as mean ± stand-
ard deviation (SD) or median (interquartile range [IQR]) 
and categorical variables as count and proportion. Com-
parisons of proportions were made using Chi-square or 
Fisher exact tests, as appropriate. Data at different times 
during  ECCO2R were compared by analysis of variance 
(ANOVA) for repeated measures. If significant (P ≤ 0.05), 
values obtained after 8 h and 24 h of  ECCO2R were com-
pared with those obtained at baseline by using paired 
Student t test adjusting P value using Bonferroni correc-
tion for multiple comparisons.
2 The study protocol (see online supplement) originally said: “aPTT ratio is 
maintained at 1.5–2.0 × baseline”. However, the case report form did not ask 
for aPTT ratio but for absolute aPTT values (see online supplement). This 
inconsistency was communicated to investigators at the beginning of the 
study and readers at the moment of publication. For the sake of transpar-
ency, we left unchanged study protocol and statement on ClinicalTrials.Gov.
3 On ClinicalTrials.Gov (NCT02282657) and in the study protocol (see 
online supplement) the primary endpoint is formalized as: “achievement 
of VT reduction to 4 mL/kg while maintaining pH and  PaCO2 to ± 20% of 
baseline values obtained at VT of 6  mL/kg”. This formulation contains an 
obvious error that is the phrase “maintaining pH to ± 20% of baseline val-
ues”. Such variability of pH in fact does not make sense, allowing pH values 
ranging between 5.92 and 8.88. To avoid confusion and bias we (a) clarified 
the issue on the protocol with investigators at the beginning of the study; (b) 
left unchanged the statement on ClinicalTrials.Gov informing the readers 
about the mistake at the moment of publication.
No assumptions were made for missing data. Statisti-
cal analyses were performed using R (version 3.5.1). All 
p values were two-sided and values < 0.05 were deemed 
significant. The statistical analysis plan is available online.
Results
Of the 483 patients matching entry criteria, 95 patients 
were enrolled between October 2015 and June 2017 at 23 
centers in Europe and Canada. Thirty-three patients were 
treated with the Hemolung device at five sites. Ten sites 
used the iLA activve device and treated 34 patients; eight 
sites used the  Cardiohelp® HLS 5.0 device and treated 28 
patients (Fig. 1). The centers enrolled a median of 3 [1–5] 
patients. Baseline characteristics and concomitant treat-
ments at inclusion are shown in Table 1. No patient was 
lost to follow-up.
The proportion of patients who achieved ultra-protec-
tive settings by 8 h and 24 h was 78% (confidence inter-
val 68–89%) (74 out of 95) and 82% (confidence interval 
76–88%) (78 out of 95), respectively.  ECCO2R was main-
tained for 5 [3–8] days.
Cannulation was performed through the internal jugu-
lar vein in 57% and through the femoral vein in 43% of 
patients. Catheter size was 15.5  Fr in patients on the 
Hemolung device and 18 [18–20]  Fr in patients on the 
iLA activve and  Cardiohelp® HLS 5.0 devices (p < 0.001). 
Operational characteristics of  ECCO2R are shown in 
Table 2.
The time course of the respiratory variables in the first 
24  h is reported in Fig.  2. VT, respiratory rate, minute 
ventilation, PPLAT, and ∆P were significantly lower at 8 h 
and 24 h compared to baseline (p = 0.001). Compared to 
baseline,  PaCO2 and  PaO2/FiO2 ratio remained stable, 
while pH significantly increased at 8 h (p < 0.05) and 24 h 
(p < 0.001). Trend of respiratory variables until  ECCO2R 
discontinuation was consistent with the one observed in 
the first 24 h (Table 1_online supplement).
Six SAE were reported (massive right frontal paren-
chymal hematoma, severe hematemesis and melena, 
superior vena cava thrombosis; sudden death, severe 
hypoxemia, pneumothorax at cannula insertion in the 
Patients matching entry criteria (October 2015-June 2017):
• Moderate ARDS
• ≥ 18 years
• Expected to receive invasive mechanical ventilation for >24 hours
N= 755
Exclusion criteria:
• Pregnancy = 2
• Decompensated heart insufficiency or acute coronary syndrome = 45
• Severe Chronic Obstructive Pulmonary Disease = 56
• Major respiratory acidosis with PaCO2 >60 mmHg = 74
• Acute brain injury = 86
• Severe liver insufficiency (Child-Pugh scores >7) or fulminant hepatic failure = 42
• Heparin-induced thrombocytopenia = 4
• Contraindication for systemic anticoagulation = 186
• Platelet <50 G/l = 36
• Patient moribund, decision to limit therapeutic interventions = 45
• Catheter access to femoral vein or jugular vein impossible = 3
• Pneumothorax = 9
• Refused consent = 52
• Included in other trials = 20
N= 660
Included in the trial and treated with ECCO2R:
• Hemolung = 33
• iLAACTIVVE = 34
• Cardiohelp® = 28
N= 95
Fig. 1 Study flow chart
Table 1 Characteristics of patients at study inclusion
Data are mean (standard deviation) or median [interquartile range]
BMI body mass index, SAPS simplified acute physiological score, SOFA sequential 
organ failure assessment, VT tidal volume, RR respiratory rate, VE minute 
ventilation, PPLAT end-inspiratory plateau pressure, PEEP positive end-expiratory 
pressure, ∆P delta pressure (ΔP = PPLAT minus PEEP), PaCO2 partial pressure of 
arterial  CO2, PaO2 arterial oxygen fraction, FiO2 inspiratory oxygen fraction, PaO2/
FiO2 ratio of arterial-to-inspiratory oxygen fraction
Age (years) 60.2 ± 14.0
Female (n, %) 31 (32.6%)
BMI (kg/m2) 29.2 ± 8.79
SAPS II 45.9 ± 15.5
SOFA score 7.42 ± 3.22
Cause of ARDS (n, %)
 Pneumonia 78 (82.1%)
 Non-pulmonary sepsis 3 (3.2%)
 Pancreatitis 2 (2.1%)
 Pulmonary contusion 2 (2.1%)
 Other 10 (10.5%)
Ventilatory settings
 VT (mL/kg) 6.0 ± 0.2
 RR (breaths/min) 27.3 ± 4.8
 VE (L/min) 10.2 ± 2.3
 PEEP  (cmH2O) 15.5 [10.0;16.0]
 PPLAT (breaths/min) 26.6 ± 3.0
 ΔP  (cmH2O) 13.2 ± 4.3
 PaCO2 (mmHg) 47.8 ± 9.4
 pH 7.34 ± 0.08
 FiO2 0.57 [0.50;0.70]
 PaO2 (mmHg) 101.2 ± 34.5
 PaO2/FiO2 173 ± 61
Adjunctive treatments before inclusion (n, %)
 Muscle paralysis 80 (84.2%)
 Prone position 23 (24.2%)
 Pulmonary vasodilator 8 (8.42%)
 Recruitment maneuvers 26 (27.4%)
internal jugular vein). Two SAEs (massive right frontal 
parenchymal hematoma and pneumothorax at cannula 
insertion in the internal jugular vein) were considered 
attributable to  ECCO2R.  ECCO2R-AE were reported in 
37 patients (39%). Adverse events occurred in the first 
24 h of  ECCO2R in 26 patients (Table 3).
Duration of invasive mechanical ventilation was 17 
[11–29]  days. A total of 69 patients (73%) were alive at 
day 28. Fifty-nine patients (62%) were alive at hospital 
discharge. Ventilator-free days were 11 [0–17] days.
Discussion
This study shows that  ECCO2R can be used to minimize 
respiratory acidosis while applying an ultra-protective 
ventilatory strategy in patients with moderate ARDS. 
However, the relatively high numbers of observed adverse 
events confirm the need for randomized clinical trial(s) 
to assess if benefits outweigh the risks.
A number of lung protective strategies such as decreas-
ing PPLAT, driving pressure, power, respiratory rate, or 
tidal volume have been suggested to decrease VILI. These 
approaches are often associated with hypercapnia and 
respiratory acidosis [18]. Although hypercapnia may 
be well tolerated [19], there are a number of important 
side effects [20, 21], and recent data suggest an associa-
tion between values of  PaCO2 > 50 mmHg and increased 
mortality [22]. In the present study we tested the effi-
cacy of  ECCO2R to decrease tidal volume below 6 mL/kg 
because it is the variable most commonly associated with 
lung protective strategies, has a clear physiologic linkage 
to  CO2 removal, and has been studied in previous studies 
[6, 8, 9, 11].
Recent data have demonstrated that there is no 
safe upper limit for PPLAT or ΔP [13, 23]. For exam-
ple, the mortality rate in ARDS patients with ΔP val-
ues ≤ 14  cmH2O is still as high as 20% [13, 23]. Patient 
outcomes may therefore be improved by aggressively 
lowering ventilatory variables such as VT, PPLAT, or ΔP 
as facilitated by  ECCO2R devices that remove  CO2. In 
addition,  ECCO2R might further decrease VILI by allow-
ing lower respiratory rates, which have been shown to be 
lung protective [12], perhaps by decreasing mechanical 
power delivered to the lungs [14].
A few studies have examined the feasibility of ultra-
protective ventilation facilitated by  ECCO2R. Two studies 
were single-center studies and included small numbers 
of patients [6, 10]. Other multicenter observational [8, 9] 
or randomized [11] studies treated patients with a single 
device. A survey of 239 French intensive care units found 
that 15% of the units used  ECCO2R at least once (total 
Table 2 Operational characteristics of extracorporeal  CO2 removal
Data are mean (standard deviation) or median [interquartile range]
*p < 0.05 lower vs. higher  CO2 extraction
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49.1 ± 14.9 57.6 ± 21.6
Table 3 Numbers of patients experiencing  ECCO2R‑related 
adverse events occurring between enrollment and day 28
ECCO2R extracorporeal carbon dioxide removal. Hemolysis: serum free 
hemoglobin ≥ 100 mg/L or hematocrit reduction not related to hemorrhage or 
other causes of blood loss, jaundice, hemoglobinuria, impaired renal function; 
significant bleeding: any bleeding event requiring administration of 1 unit of 
packed red cells; thrombocytopenia: platelet count below 50,000 per microliter; 
hypofibrinogenemia: fibrinogen < 1.5 g/L
ECCO2R-related adverse events Patients experiencing 
 ECCO2R-related adverse 
events, n (%)
Mechanical
 Membrane lung clotting 13 (14)
  Leading to circuit change 6 (6)
  Leading to  ECCO2R discontinuation 7 (7)
 Pump malfunction 3 (3)
 Catheter displacement 2 (2)
Clinical
 Hemolysis 11 (12)
 Bleeding 13 (14)
  Related to cannula insertion 3 (3)
  At cannula site 7 (7)
  Significant 6 (6)
 Infectious complications 2 (2)
 Thrombocytopenia 12 (13)
 Hypofibrinogenemia 2 (2)
of 303 patients) from January 2010 to January 2015, and 
that the most frequent indication was ultra-protective 
ventilation for ARDS (54%) [15].
A major strength of this study is the relatively large 
number of patients, from multiple centers in Europe and 
Canada. At the same time, the following major limita-
tions of the study should be acknowledged: First, analy-
sis of  ECCO2R safety may be somewhat underpowered 
in that we only studied 95 patients. Second, although 
originally planned as secondary endpoints (see Clinical-
Trials.Gov Identifier NCT02282657) we were not able 
to quantify clearance and total amount of  CO2 removed 
by  ECCO2R. Recent experimental data show that these 
measurements are essential to assess effectiveness of  CO2 
removal capacity during  ECCO2R [24]. Third, although 
sample size was inflated to take into consideration a pos-
sible 3% of dropout due to  ECCO2R malfunction, we 
studied 95 out of the 100 patients planned as a result 
of lack of equipment during the final phase of the study 
period.
Assessment of safety in the context of a large interna-
tional cohort of patients is of paramount importance for 
the clinical implementation of  ECCO2R and to move to 
a phase III randomized clinical trial. Previous data on 
safety of  ECCO2R to support ultra-protective ventila-
tion are limited to three small case series all using lower 
Fig. 2 Time course of respiratory variables. VT tidal volume, RR respiratory rate, VE minute ventilation, PPLAT end-inspiratory plateau pressure, PEEP 
positive end-expiratory pressure, ∆P delta pressure (ΔP = PPLAT minus PEEP),  PaCO2 partial pressure of arterial  CO2,  PaO2/FiO2 ratio of arterial-to-inspir-
atory oxygen fraction. #P < 0.05 vs baseline. *P < 0.001 vs baseline
extraction devices. In a single-center study, Terragni and 
coworkers reported only adverse mechanical events that 
occurred in 8 out of the 10 patients [6]. Fanelli and cow-
orkers in a four-center study that included 15 patients 
reported bleeding in 7 patients, hemolysis in 1 patient, 
and catheter kinking in 1 patient [8]. Schmidt and cow-
orkers in a five-center study that included 20 patients 
reported bleeding in 2 patients and membrane-lung 
clotting in 10 patients [9]. A randomized clinical trial 
that included 79 patients from eight sites and that used 
a pumpless arterial-venous  ECCO2R device showed that 
the number of units of red blood cells transfused was 
significantly higher in the  ECCO2R group compared 
with control (3.7 ± 2.4 vs. 1.5 ± 1.3%, p < 0.05) but the 
incidence of  ECCO2R-related adverse events was low (3 
patients; 7.5%) [11].
ECCO2R-AE were a priori defined and collected sys-
tematically.  ECCO2R-AE were observed in 39% of 
patients; 70% of these patients experienced adverse 
events in the first 24 h of  ECCO2R. Bleeding and hemoly-
sis were the most common  ECCO2R-AEs. An independ-
ent DSMB adjudicated SAEs as attributable or not to 
 ECCO2R. Six SAEs were reported. The DSMB consid-
ered only two as attributable to  ECCO2R: a massive right 
frontal parenchymal hematoma, and a pneumothorax 
secondary to cannula insertion in the internal jugular 
vein. With respect to bleeding episodes, events requiring 
administration of at least 1 unit of packed red cells were 
reported in 6% of patients.
These data strongly support the need for a well-
designed randomized clinical trial to confirm that the 
clinical benefits of an ultra-protective strategy supported 
by  ECCO2R would compensate for the serious side 
effects associated with  ECCO2R. The REST trial (pRotec-
tive vEntilation with veno-venouS lung assisT in respira-
tory failure; NCT02654327) is currently ongoing and is 
randomly assigning adult patients with acute hypoxemic 
respiratory failure  (PaO2/FiO2 < 150  mmHg) to either 
conventional lung protective ventilation or  ECCO2R 
using a lower extraction device (Hemolung Respiratory 
Assist System; ALung Technologies, Pittsburgh, USA). 
Given the relatively high risk of adverse events, future tri-
als might aim to enhance the ratio of benefit to risk by 
selecting patients likely to have the greatest clinically rele-
vant physiological response, as suggested previously [25]. 
However, data of the present study outline the difficul-
ties a prospective randomized clinical trial on  ECCO2R 
may incur. First, only 12.6% of the patients admitted in 
the study period for moderate ARDS could be enrolled 
and treated with  ECCO2R. Second, contraindications 
for systemic anticoagulation and bleeding disorders 
(heparin-induced thrombocytopenia; platelet < 50  G/L) 
were observed in 30% of patients, thus limiting a wider 
use of  ECCO2R in the clinical settings. Third, although 
we included study centers with substantial experience 
in  ECCO2R, only 3 [1–5] patients per site were enrolled 
during the 21-month study period. These data empha-
size the importance of providing a learning curve for the 
use of  ECCO2R to those centers that, although without 
specific experience, will have to be included in the study 
to allow the recruitment of a sufficiently large number of 
patients.
In conclusion, this study demonstrates that ultra-
protective ventilation facilitated by  ECCO2R is feasible, 
mitigating respiratory acidosis in patients with moderate 
ARDS. A randomized clinical trial is required to assess 
overall benefits and harms.
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